首页> 美国卫生研究院文献>Frontiers in Oncology >ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy

【2h】

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy

机译：ESR1突变不是新辅助芳香化酶抑制剂治疗的雌激素受体阳性乳腺癌患者内分泌抵抗的常见机制。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Frontiers in Oncology
作者
Tomás Reinert; Susana Ramalho; Vivian Castro Antunes de Vasconcelos; Leonardo Roberto Silva; Ana Elisa Ribeiro da Silva; Camila Annicchino de Andrade; Maria Beatriz de Paula Leite Kraft; Guilherme Portela Coelho; Jovana Mandelli; Monique Binotto; Cesar Cabello; Geisilene Russano de Paiva Silva; José Bines; Carlos H. Barrios; Matthew J. Ellis; Marcia Silveira Graudenz;
展开▼
作者单位

展开▼
年(卷),期 2020(10),-1
年度 2020
页码 -1
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
breast cancer; endocrine therapy;

机译：乳腺癌;内分泌治疗;

相似文献

外文文献
中文文献
专利

1. ESR1 mutations are not a mechanism of primary resistance to aromatase inhibitors in ER-positive breast cancer treated with neoadjuvant endocrine therapy [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：ESR1突变不是用Neoadjuvant内分泌治疗治疗的ER阳性乳腺癌中芳香酶抑制剂的常规抗性的机制
2. Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. [J] . Monica S M Chan, Lin Wang, Niramol Chanplakorn, Expert opinion on therapeutic targets . 2012,第S1期

机译：雌激素耗竭对雌激素受体阳性乳腺癌血管生成的影响-新辅助芳香化酶抑制剂治疗中vasohibin-1和CD31的免疫组织化学研究与患者的病理生物学反应相关。
3. Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. [J] . Monica S M Chan, Lin Wang, Niramol Chanplakorn, Expert opinion on therapeutic targets . 2012,第S1期

机译：雌激素耗尽对雌激素受体阳性乳腺癌血管生成的影响 - vasohibin-1和CD31的免疫组化研究与新辅助芳香酶抑制剂治疗患者病理学响应的相关性。
4. A Single Tube Screening of Endocrine Therapy Resistance ESR1 Mutations in ER-Positive Breast Cancer [C] . Akihiro Tsuyada, Shunsuke Nakano, Toshimitsu Ichijo, International Molecular Medicine Tri-Conference. . 2016

机译：ER阳性乳腺癌内分泌治疗抗ESR1突变的单管筛选
5. Adipsin Is an ERα Target Gene that Leads to Endocrine Resistance in Breast Cancer with ESR1 Mutations [D] . Malone, Marie Kathryn. 2020

机译：Adipsin是一种ERα靶基因，导致ESR1突变的乳腺癌内分泌抵抗力
6. Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative Lymph Node-Positive Breast Cancer [O] . Sungchan Gwark, Sei Hyun Ahn, Woo Chul Noh, 2021

机译：患者报告的III期Neoadjuvant Systemic试验的结果将Neoadjuvant化疗与Neoadjuvant内分泌治疗进行雌激素受体阳性和Her2阴性淋巴结阳性乳腺癌中预期患者的新辅助内分泌治疗
7. ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy [O] . Tomás Reinert, Susana Ramalho, Vivian Castro Antunes de Vasconcelos, 2020

机译：ESR1突变不是用Neoadjuvant芳香酶抑制剂治疗治疗的雌激素受体阳性乳腺癌患者内分泌抗性的常见机制

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy

著录项

相似文献

相关主题

期刊订阅